The NIAID labs met the 2009 H1N1 research challenge with vigilance, planning, and strong public health research capability.
Learn how immunizing a critical portion of a community protects most members of the community.
The 2009 outbreak of a new strain of H1N1 influenza A demonstrated that continuing vigilance, planning, and strong public health research capability are essential defenses against emerging health threats.
Past research on H5N1 (bird flu) as well as other influenza viruses with potential to create pandemics prepared NIAID scientists to respond to this newest influenza threat. Researchers expanded and refocused projects to include studies of the course of the virus, the origin of the virus, H1N1-infected patients, and a preventive vaccine. Many of these studies involve collaborations with other federal agencies, academia, and the private sector. Scientific findings continue to shed light on the mysteries of influenza, and will help researchers create better, faster vaccine production techniques, and better treat severely ill people.
Web Bulletin: Antibodies Identified after 2009 H1N1 Infection Neutralize Multiple Flu Virus Strains—Jan. 12, 2011
2009 H1N1 Vaccine Safe and Induces Robust Immune Response in People with Asthma—Dec. 13, 2010
Q&A: NIH Trial of 2009 H1N1 Influenza Vaccine in People with Asthma—Dec. 13, 2010
Bulletin: NIAID Testing Candidate DNA Vaccine for 2009 H1N1 Influenza—Dec. 11, 2009
All Flu News Releases
News from NIAID-Supported Institutions
Recent Congressional Testimony by Anthony S. Fauci, MD, NIAID Director
Last Updated November 29, 2011
Last Reviewed January 12, 2011